Virtus ETF Advisers LLC Chemo Centryx, Inc. Transaction History

Virtus ETF Advisers LLC

$206 Million
Q3 2024

Shares

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Nov 14, 2022	BUY	$22.17 - $51.8 $3,192 - $7,459	144 Added 1.45%	10,074 $520,000
Q2 2022 Aug 12, 2022	SELL	$15.36 - $27.51 $19,722 - $35,322	-1,284 Reduced 11.45%	9,930 $246,000
Q4 2021 Feb 14, 2022	SELL	$18.38 - $40.5 $90,576 - $199,584	-4,928 Reduced 30.53%	11,214 $408,000
Q3 2021 Nov 15, 2021	SELL	$13.18 - $19.83 $11,110 - $16,716	-843 Reduced 4.96%	16,142 $276,000
Q2 2021 Aug 10, 2021	BUY	$9.59 - $50.88 $117,151 - $621,550	12,216 Added 256.15%	16,985 $227,000
Q1 2021 May 17, 2021	BUY	$49.53 - $68.4 $3,714 - $5,130	75 Added 1.6%	4,769 $244,000
Q4 2020 Feb 12, 2021	SELL	$47.25 - $65.16 $1,795 - $2,476	-38 Reduced 0.8%	4,694 $291,000
Q3 2020 Nov 13, 2020	SELL	$46.35 - $61.69 $30,312 - $40,345	-654 Reduced 12.14%	4,732 $259,000
Q2 2020 Aug 05, 2020	SELL	$38.58 - $65.07 $233,833 - $394,389	-6,061 Reduced 52.95%	5,386 $310,000
Q1 2020 May 14, 2020	SELL	$32.73 - $50.78 $54,593 - $84,701	-1,668 Reduced 12.72%	11,447 $460,000
Q4 2019 Feb 13, 2020	SELL	$6.81 - $39.55 $116,934 - $679,113	-17,171 Reduced 56.7%	13,115 $519,000
Q3 2019 Nov 12, 2019	SELL	$6.47 - $8.96 $10,914 - $15,115	-1,687 Reduced 5.28%	30,286 $205,000
Q2 2019 Aug 13, 2019	BUY	$8.31 - $14.85 $45,879 - $81,986	5,521 Added 20.87%	31,973 $297,000
Q1 2019 May 14, 2019	SELL	$10.01 - $13.89 $32,032 - $44,448	-3,200 Reduced 10.79%	26,452 $367,000
Q4 2018 Feb 05, 2019	SELL	$9.15 - $12.26 $65,422 - $87,659	-7,150 Reduced 19.43%	29,652 $324,000
Q3 2018 Nov 14, 2018	SELL	$10.49 - $13.72 $283,513 - $370,810	-27,027 Reduced 42.34%	36,802 $465,000
Q2 2018 Aug 10, 2018	BUY	$10.62 - $13.98 $677,863 - $892,329	63,829 New	63,829 $841,000

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.